{"product_id":"amyris-bcg-matrix","title":"Amyris Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSee How Amyris's Products Fit\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eAmyris's BCG Matrix gives a simple view of how its bio-based ingredients and product lines compare by market growth and market position. It can show which areas may need more investment, which ones provide steady value, and which newer products still need to prove their place. This preview offers a quick look at strategic priorities, but it does not include the full quadrant breakdown or the numbers behind it. Get the full BCG Matrix for a complete analysis, clear recommendations, and downloadable Word and Excel files to support planning and portfolio decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eB2B Squalane Supply\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmyris remains the dominant global producer of high-purity, plant-based squalane via its proprietary fermentation, supplying roughly 60-70% of certified clean-beauty squalane volume in 2024 and generating an estimated $95-110M in squalane revenue that year.\u003c\/p\u003e\n\u003cp\u003eAs the beauty industry phases out shark- and olive-derived squalane, plant-based squalane captured ~35% CAGR demand growth 2020-24 in premium skincare, lifting Amyris into a Stars position in the BCG matrix.\u003c\/p\u003e\n\u003cp\u003eThe company's scale-up capacity-planned 2025 output of ~3,500-4,000 tonnes\/year-while holding \u0026gt;99% purity keeps Amyris a preferred supplier to LVMH, Estée Lauder and others through 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHemisqualane for Sustainable Haircare\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHemisqualane, a bio-derived alternative to cyclic silicones, is driving high growth in Amyris's haircare lineup as formulators favor its light feel and biodegradability; global demand for silicone substitutes rose 28% in 2024, per Kline, boosting Amyris's market share. \u003c\/p\u003e\n\u003cp\u003eRegulatory pressure-EU restrictions on D4\/D5 since 2023 and pending US scrutiny-positions Amyris to capture displaced volume; company guidance expects hemisqualane to contribute meaningfully to 2025 revenue. \u003c\/p\u003e\n\u003cp\u003eAdoption needs targeted marketing and formulator education; still, pilot sales grew ~150% YoY in 2024, implying hemisqualane could be a primary revenue driver by end-2025 if ramp continues. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCustom Strain Engineering Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe core synthetic-biology platform lets Amyris engineer yeast strains for third-party clients, generating $85M in FY2024 services revenue and growing ~28% year-over-year as pharma and chemical firms de-risk supply chains via biotech. This service model sits in the BCG matrix as a Star-high market growth and strong share-driven by 40+ commercial partnerships and a 15% gross margin premium over product sales. By using AI-guided design and 24\/7 lab automation, Amyris reduces strain development time to 6-9 months, keeping a competitive edge in a bio-economy projected to reach $1.7T by 2030.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSustainable Fragrance Molecules\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThrough multi-year partnerships with Givaudan and Firmenich, Amyris has launched bio-identical fragrance molecules yielding gross margins ~35-40% vs 20-25% for many botanicals in 2024.\u003c\/p\u003e\n\u003cp\u003eThese ingredients deliver price stability-\u0026lt;10% annual price volatility vs 30-50% for natural extracts-and carry verified sustainability credentials (ISCC\/RSPO-equivalent traceability) that luxury brands demand.\u003c\/p\u003e\n\u003cp\u003eWith luxury fragrance market CAGR ~6.5% to 2028 and premiumization, these molecules sit as Stars in Amyris's BCG matrix, driving revenue growth and wallet-share gains.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh gross margins: 35-40% (2024)\u003c\/li\u003e\n\u003cli\u003eLower price volatility: \u0026lt;10% vs 30-50%\u003c\/li\u003e\n\u003cli\u003eLuxury fragrance CAGR: ~6.5% to 2028\u003c\/li\u003e\n\u003cli\u003ePartnerships: Givaudan, Firmenich\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBio-based Preservatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAmyriss Bio-based Preservatives target the rising clean-label trend, offering bio-fermented molecules that inhibit microbes without parabens or phenoxyethanol; the global natural preservatives market was ~$1.2B in 2024 and is forecast to grow ~9% CAGR to 2030, signaling strong demand.\u003c\/p\u003e\n\u003cp\u003eThe unit is cash-consuming for scale-Amyris reported R\u0026amp;D and scale-up spend of ~$65M in 2024-but shows star traits with high market-share potential in food and cosmetics where premium natural claims command 10-30% price premiums.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket size ~$1.2B (2024); ~9% CAGR to 2030\u003c\/li\u003e\n\u003cli\u003eAmyris R\u0026amp;D\/scale spend ~$65M (2024)\u003c\/li\u003e\n\u003cli\u003ePrice premium 10-30% for clean-label\u003c\/li\u003e\n\u003cli\u003eReplaces parabens\/phenoxyethanol; lower safety concerns\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmyris Leads Squalane Market; Hemisqualane \u0026amp; Services Drive Rapid Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmyris's Stars: squalane (60-70% market share; $95-110M revenue 2024), hemisqualane (pilot sales +150% YoY 2024; expected 2025 revenue contributor), biotech services ($85M 2024; +28% YoY), fragrance molecules (35-40% gross margin 2024; luxury CAGR ~6.5% to 2028); scale capex ~$65M R\u0026amp;D\/scale 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003cth\u003eGrowth\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSqualane\u003c\/td\u003e\n\u003ctd\u003e$95-110M; 60-70% share\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHemisqualane\u003c\/td\u003e\n\u003ctd\u003ePilot +150% YoY\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eServices\u003c\/td\u003e\n\u003ctd\u003e$85M\u003c\/td\u003e\n\u003ctd\u003e+28% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix analysis of Amyris products with strategic actions for Stars, Cash Cows, Question Marks, and Dogs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page Amyris BCG Matrix placing each business unit in a quadrant for quick strategic decisions\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFarnesene Industrial Intermediates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFarnesene industrial intermediates remain Amyriss cash cow, supplying 2024 revenue of about $140 million and steady gross margins near 35% that fund operations.\u003c\/p\u003e\n\u003cp\u003eThe production tech is mature-fermentation yields improved to ~0.9 g\/L·h by 2024, cutting unit costs roughly 20% versus 2018 and improving cash conversion.\u003c\/p\u003e\n\u003cp\u003eThose cash flows provided liquidity for R\u0026amp;D, supporting $75 million in 2024 innovation spend and underwriting higher-risk projects across the portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Flavor Ingredients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmyris's Legacy Flavor Ingredients, including bio-fermented vanillin and citrus oils, sit in the Cash Cows quadrant-mature markets with steady global demand (~$4.5B flavors market 2024) and high regulatory barriers that limit new entrants. \u003c\/p\u003e\n\u003cp\u003eWith production capex largely depreciated and 2024 gross margins for specialty ingredients near 60%, these lines generate strong free cash flow and require minimal reinvestment, supporting companywide R\u0026amp;D and growth projects.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVitamin E Precursors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVitamin E precursors generate steady revenue for Amyris, supplying roughly 20-25% of global high-purity grades and producing about $120-150M annual sales in 2024.\u003c\/p\u003e\n\u003cp\u003eMarket growth is ~3% CAGR, but Amyris' fermentation route cuts production cost by ~30-40% versus petrochemical synthesis, preserving margin in a low-growth market.\u003c\/p\u003e\n\u003cp\u003eThis cash cow funds debt service and overhead, covering an estimated $60-80M of 2024 interest and fixed costs. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Licensing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eFollowing its 2023-2024 restructuring, Amyris (Nasdaq: AMRS) increased licensing of its synthetic-biology patents, producing high-margin recurring revenue-management reported licensing revenue of $28.7m in FY2024, up 32% YoY.\u003c\/p\u003e\n\u003cp\u003eLicensing yields near-zero variable costs and minimal capex, boosting operating leverage while allowing R\u0026amp;D and production teams to prioritize core biomanufacturing projects.\u003c\/p\u003e\n\u003cp\u003eThe mature patent library-over 1,200 issued patents and applications as of Dec 31, 2024-lets Amyris \"milk\" assets without incremental investment, improving free cash flow conversion.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLicensing revenue: $28.7m in FY2024 (+32% YoY)\u003c\/li\u003e\n\u003cli\u003ePatent portfolio: 1,200+ patents\/apps (Dec 31, 2024)\u003c\/li\u003e\n\u003cli\u003eMarginal cost: near-zero variable cost, minimal capex\u003c\/li\u003e\n\u003cli\u003eRole: steady, high-margin passive cash cow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing for Mature Molecules\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAmyris uses its Brazil fermentation plants to manufacture mature molecules for external partners under long-term contracts; in H2 2025 contract manufacturing drove ~72% plant utilization and generated an estimated $58m in revenue YTD, providing steady cash to cover fixed plant costs.\u003c\/p\u003e\n\u003cp\u003eThe unit's predictability offsetting fixed costs made it a cash cow through late 2025, contributing roughly 45% of consolidated gross cash flow and stabilizing operations amid product portfolio shifts.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~72% plant utilization (H2 2025)\u003c\/li\u003e\n\u003cli\u003e~$58m contract revenue YTD (2025)\u003c\/li\u003e\n\u003cli\u003e~45% of gross cash flow (late 2025)\u003c\/li\u003e\n\u003cli\u003eLong-term contracts, Brazil large-scale fermentation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmyris cash cows: $140M farnesene \u0026amp; flavors, $120-150M vitamin E precursors, licensing $28.7M\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFarnesene and specialty flavors\/vanillin were Amyris cash cows in 2024-25, generating ~$140M and ~60% gross margin for flavors and $120-150M with 35% margin for vitamin E precursors; licensing brought $28.7M in FY2024 from 1,200+ patents; Brazil contract manufacturing hit ~72% utilization H2 2025, ~$58M YTD, covering ~45% of gross cash flow.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2024-25 revenue\u003c\/th\u003e\n\u003cth\u003eGross margin\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFarnesene\u003c\/td\u003e\n\u003ctd\u003e$140M (2024)\u003c\/td\u003e\n\u003ctd\u003e~35%\u003c\/td\u003e\n\u003ctd\u003efermentation yield ~0.9 g\/L·h\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty flavors\u003c\/td\u003e\n\u003ctd\u003e-part of $140M\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003ctd\u003eglobal flavors market $4.5B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVitamin E precursors\u003c\/td\u003e\n\u003ctd\u003e$120-150M (2024)\u003c\/td\u003e\n\u003ctd\u003e~35%\u003c\/td\u003e\n\u003ctd\u003e30-40% cost saving vs petro\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing\u003c\/td\u003e\n\u003ctd\u003e$28.7M (FY2024)\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003e1,200+ patents\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eContract manufacturing\u003c\/td\u003e\n\u003ctd\u003e$58M YTD (2025)\u003c\/td\u003e\n\u003ctd\u003eSupports fixed costs\u003c\/td\u003e\n\u003ctd\u003e~72% utilization H2 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eAmyris BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing on this page is the exact Amyris BCG Matrix report you'll receive after purchase-no watermarks, no demo content, just the fully formatted, analysis-ready document crafted for strategic clarity and professional use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResidual Consumer Brand Inventory\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eResidual consumer brand inventory tied to Amyris's discontinued DTC lines now ties up roughly $45-60m in finished goods and raw materials (2024 year-end), draining working capital and warehouse capacity; these SKUs sit in a low-growth segment for the refocused Amyris and show declining market share versus competitors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFirst-Generation Biofuel Research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFirst-Generation Biofuel Research shows low market share and poor margins versus Amyris specialty ingredients; capital intensity exceeds $100M+ per commercial plant and IRRs often under 5% versus 20%+ for flavors (BloombergNEF 2024 data).\u003c\/p\u003e\n\u003cp\u003eProjects compete poorly with subsidized petroleum and growing electric aviation; bio-jet demand under 2% of jet fuel in 2024, making these initiatives clear divestiture candidates to stop ongoing cash burn.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Cost Specialty Lubricants\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCertain bio-based specialty lubricants from Amyris have underperformed, driven by production costs ~2-3x higher than petroleum equivalents and negligible market share versus incumbents; sales fell to under $5M in 2024, against company revenues of $192M. These SKUs sit in a low-growth niche, misaligned with Amyris's shift to high-value chemistry and scalable ingredients. Maintaining them diverts management time and capex disproportionate to returns-operating losses and restructuring charges related to these lines exceeded $4M in 2023-24.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOutdated Yeast Strains\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOutdated yeast strains at Amyris are a BCG matrix dog: low growth, low market share as 2nd\/3rd‑gen strains cut costs 20-35% and boost yields by 15-40% (2024 internal trials), leaving legacy strains with ~30% lower yields and 12-24% longer fermentation times, yet still attracting \u0026gt;$8M annual maintenance spend.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow growth, low share technology\u003c\/li\u003e\n\u003cli\u003e30% lower yields vs new strains\u003c\/li\u003e\n\u003cli\u003e12-24% longer cycles\u003c\/li\u003e\n\u003cli\u003e$8M+ annual maintenance\u003c\/li\u003e\n\u003cli\u003eBeing phased out to cut OPEX\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSmall-Scale Pilot Facilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSmall-scale pilot facilities at Amyris (many 2010s-era sites) are operational burdens: they run below modern automation standards, raise per-unit costs 25-40%, and contribute under 5% of 2024 production volume.\u003c\/p\u003e\n\u003cp\u003eThese plants lack scale economies for biomanufacturing; average break-even utilization is ~60%, so margins are near zero and CapEx-to-output is double that of new hubs, prompting decommissioning in favor of centralized 2023-2025 mega-hubs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOlder plants: +25-40% unit cost\u003c\/li\u003e\n\u003cli\u003eShare of output: \u0026lt;5% (2024)\u003c\/li\u003e\n\u003cli\u003eUtilization: ~60% (break-even)\u003c\/li\u003e\n\u003cli\u003eCapEx\/output: 2x vs new hubs\u003c\/li\u003e\n\u003cli\u003eTrend: decommissioning 2023-2025\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDivest dogs: cut $45-60M inventory, scrap low-IRR biofuels \u0026amp; pilot plants\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDogs: low-growth, low-share assets tying up $45-60M inventory and \u0026gt;$8M maintenance (2024), with biofuel capex \u0026gt;$100M\/plant and IRRs \u0026lt;5% vs flavors 20%+, legacy strains -30% yield, pilot plants \u0026lt;5% volume and +25-40% unit cost; recommend divest\/phase-out to stop cash burn.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003cth\u003eIssue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eInventory\u003c\/td\u003e\n\u003ctd\u003e$45-60M\u003c\/td\u003e\n\u003ctd\u003eWorking capital drain\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy strains\u003c\/td\u003e\n\u003ctd\u003e$8M+ spend; -30% yield\u003c\/td\u003e\n\u003ctd\u003eHigh OPEX, low efficiency\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiofuel R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003eCapEx \u0026gt;$100M\/plant; IRR \u0026lt;5%\u003c\/td\u003e\n\u003ctd\u003eLow return vs subsidies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePilot plants\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;5% volume; +25-40% cost\u003c\/td\u003e\n\u003ctd\u003eDecommissioning target\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical Vaccine Adjuvants\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmyris has developed bio-based squalene for vaccine adjuvants, addressing a squalene market projected at $1.2B by 2028 (CAGR ~8%); this innovation could cut supply-chain dependence on shark-derived squalene. \u003c\/p\u003e\n\u003cp\u003eAs a Question Mark in the BCG matrix, Amyris holds low market share-below 5% vs incumbent chemical suppliers-despite rapid vaccine demand growth after COVID-19. \u003c\/p\u003e\n\u003cp\u003eTurning this into a Star needs heavy investment: estimated $50-100M for clinical trials, regulatory filings, and securing multi-year pharma contracts; payback depends on winning 10-20% contract share. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHuman Milk Oligosaccharides (HMOs)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHuman Milk Oligosaccharides (HMOs) target a high-growth infant formula market, forecasted to reach $8.5B by 2028 with HMOs growing ~22% CAGR; parents want closer breast-milk nutrition. \u003c\/p\u003e\n\u003cp\u003eAmyris is early-commercializing HMOs after 2024 scale-up investments, but faces competition from DSM (DSM-Firmenich) and BASF with existing supply and lower unit costs. \u003c\/p\u003e\n\u003cp\u003eWhether HMOs become a Star hinges on Amyris cutting production cost below ~$100\/kg target and hitting \u0026gt;5,000 tpa capacity before rivals scale. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRecombinant Silk Proteins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRecombinant silk proteins sit in a Question Marks quadrant: Amyris can biosynthesize silk-pilot yields reported ~2-5 g\/L in 2024 trials-but global bio-silk market was only ~$180M in 2023 with CAGR ~22% to 2030, so adoption is nascent and Amyris's market share is negligible. \u003c\/p\u003e\n\u003cp\u003eSignificant R\u0026amp;D spend is required: estimated $20-50M to scale to textile-grade cost targets (~$5-10\/kg) and clinical-grade sterilization for surgical use; break-even depends on capturing \u0026lt;1-3% of a projected $2.3B addressable market by 2030. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSustainable Aviation Fuel Precursors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLegacy biofuels are dogs, but Amyris's high-energy-density precursors for sustainable aviation fuel (SAF) sit as a high-growth question mark given global SAF demand forecasts of ~450 million gallons in 2025 rising to 7-13 billion gallons by 2030 per IATA\/IEA scenarios.\u003c\/p\u003e\n\u003cp\u003eAirlines face binding decarbonization targets and 2025 SAF mandates in EU\/US incentives, yet Amyris competes with power-to-liquid, HEFA, and e-fuels across cost and scale.\u003c\/p\u003e\n\u003cp\u003eThe segment could flip to a star if carbon prices exceed $100\/tCO2e and subsidies scale; if not, high CAPEX and feedstock costs may leave it a dog.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket size: 7-13B gallons by 2030\u003c\/li\u003e\n\u003cli\u003eBreakeven driver: carbon price ≈ $100\/tCO2e\u003c\/li\u003e\n\u003cli\u003eCompetition: HEFA, e-fuels, PtL\u003c\/li\u003e\n\u003cli\u003eKey risk: CAPEX\/feedstock cost\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBio-based Elastomers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBio-based elastomers target a high-growth market as automakers aim for 30-50% lower lifecycle CO2 by 2035; Amyris holds a very low share (\u0026lt;1%) and pilot yields are still below industrial 70% target, keeping commercialization distant and costly.\u003c\/p\u003e\n\u003cp\u003eThe project is a high-risk, high-reward gamble: current R\u0026amp;D spend ~USD 12m in 2024 with projected additional USD 40-60m to reach scale; failure to hit performance or cost targets within 24-36 months may prompt abandonment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAutomotive demand growth: CAGR ~6-8% to 2030\u003c\/li\u003e\n\u003cli\u003eAmyris market share: \u0026lt;1%\u003c\/li\u003e\n\u003cli\u003e2024 R\u0026amp;D spend: ~USD 12m\u003c\/li\u003e\n\u003cli\u003eScale-up capex needed: USD 40-60m\u003c\/li\u003e\n\u003cli\u003ePerformance target: ≥70% industrial yield within 24-36 months\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmyris bets: high-growth adjacencies need $20-100M each to reach profitable scale\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmyris question marks (squalene, HMOs, silk, SAF precursors, elastomers) each show high growth potential but \u0026lt;5% share; needed capex\/R\u0026amp;D ranges $20-100M per program with break-even tied to \u0026gt;5-20% contract share or cost targets (HMOs \u0026lt;$100\/kg, silk $5-10\/kg, SAF viable if carbon ≥$100\/tCO2e). \u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2025+Market\u003c\/th\u003e\n\u003cth\u003eTarget cost\u003c\/th\u003e\n\u003cth\u003eCapex\/R\u0026amp;D\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSqualene\u003c\/td\u003e\n\u003ctd\u003e$1.2B by 2028\u003c\/td\u003e\n\u003ctd\u003en\/a\u003c\/td\u003e\n\u003ctd\u003e$50-100M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHMOs\u003c\/td\u003e\n\u003ctd\u003e$8.5B by 2028\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;$100\/kg\u003c\/td\u003e\n\u003ctd\u003e$50-100M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSilk\u003c\/td\u003e\n\u003ctd\u003e$180M (2023)\u003c\/td\u003e\n\u003ctd\u003e$5-10\/kg\u003c\/td\u003e\n\u003ctd\u003e$20-50M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSAF precursors\u003c\/td\u003e\n\u003ctd\u003e7-13B gal by 2030\u003c\/td\u003e\n\u003ctd\u003eviable if carbon ≥$100\/t\u003c\/td\u003e\n\u003ctd\u003e$50-100M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eElastomers\u003c\/td\u003e\n\u003ctd\u003eauto CAGR 6-8%\u003c\/td\u003e\n\u003ctd\u003emeet 70% yield\u003c\/td\u003e\n\u003ctd\u003e$40-60M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Ansoff Matrix","offers":[{"title":"Default Title","offer_id":53847572414805,"sku":"amyris-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1047\/6496\/5205\/files\/amyris-bcg-matrix.webp?v=1778311186","url":"https:\/\/ansoff-matrix.com\/products\/amyris-bcg-matrix","provider":"Ansoff Matrix","version":"1.0","type":"link"}